MSN Pharmaceuticals' New Jersey manufacturing facility receives US FDA approval
23 December 2021 -

United States-based Novadoz Pharmaceuticals announced on Wednesday that its corporate group entity, MSN Pharmaceuticals, has received approval from United States Food and Drug Administration (FDA) audit with zero observations for its new, 200,000 sq. ft. manufacturing facility in Piscataway, New Jersey.

The new facility is to produce high quality, generic pharmaceuticals to include both oral solids and liquids. It will include a modern lab and executive offices for both MSN Pharmaceuticals and Novadoz Pharmaceuticals.

The company has also received approval for generic Tiagabine (AB rated to Gabitril). Tiagabine 2mg, 4mg, 12mg & 16mg tablets are offered in bottles of 30. The product is indicated as adjunctive treatment for partial seizures in patients age 12-years and older.



Related Headlines